| Literature DB >> 25609853 |
A Achalandabaso1, G Plaza-Manzano2, R Lomas-Vega3, A Martínez-Amat3, M V Camacho4, M Gassó4, F Hita-Contreras3, F Molina3.
Abstract
Spinal manipulation (SM) is a manual therapy technique frequently applied to treat musculoskeletal disorders because of its analgesic effects. It is defined by a manual procedure involving a directed impulse to move a joint past its physiologic range of movement (ROM). In this sense, to exceed the physiologic ROM of a joint could trigger tissue damage, which might represent an adverse effect associated with spinal manipulation. The present work tries to explore the presence of tissue damage associated with SM through the damage markers analysis. Thirty healthy subjects recruited at the University of Jaén were submitted to a placebo SM (control group; n = 10), a single lower cervical manipulation (cervical group; n = 10), and a thoracic manipulation (n = 10). Before the intervention, blood samples were extracted and centrifuged to obtain plasma and serum. The procedure was repeated right after the intervention and two hours after the intervention. Tissue damage markers creatine phosphokinase (CPK), lactate dehydrogenase (LDH), C-reactive protein (CRP), troponin-I, myoglobin, neuron-specific enolase (NSE), and aldolase were determined in samples. Statistical analysis was performed through a 3 × 3 mixed-model ANOVA. Neither cervical manipulation nor thoracic manipulation did produce significant changes in the CPK, LDH, CRP, troponin-I, myoglobin, NSE, or aldolase blood levels. Our data suggest that the mechanical strain produced by SM seems to be innocuous to the joints and surrounding tissues in healthy subjects.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25609853 PMCID: PMC4291009 DOI: 10.1155/2014/815379
Source DB: PubMed Journal: Dis Markers ISSN: 0278-0240 Impact factor: 3.434
Sociodemographic characteristics and baseline measures of the groups.
| Characteristic | Control | Thoracic | Cervical |
| ||||
|---|---|---|---|---|---|---|---|---|
| Age* (years) | 27.60 ± 3.22 | 29.80 ± 3.52 | 28.60 ± 3.99 | 0.195 | ||||
| BMI* | 21.45 ± 2.38 | 23.98 ± 3.97 | 23.17 ± 2.94 | 0.206 | ||||
| Weight* (Kg) | 66.60 ± 8.47 | 73.70 ± 14.33 | 71.20 ± 12.19 | 0.528 | ||||
| Height* (m) | 1.72 ± 0.07 | 1.75 ± 0.06 | 1.75 ± 0.12 | 0.301 | ||||
| CPK* (U/L) | 74.90 ± 17.21 | 72.00 ± 13.73 | 65.10 ± 14.78 | 0.353 | ||||
| LDH* (U/L) | 276.03 ± 57.30 | 297.20 ± 52.66 | 275.90 ± 43.40 | 0.573 | ||||
| Enolase* (ng/mL) | 9.48 ± 1.81 | 9.09 ± 1.50 | 9.57 ± 3.26 | 0.887 | ||||
| CPR* (mg/L) | 1.41 ± 1.00 | 0.56 ± 0.30 | 1.48 ± 1.16 | 0.056 | ||||
| Aldolase* (U/L) | 3.09 ± 1.60 | 3.10 ± 1.06 | 3.13 ± 1.02 | 0.998 | ||||
| Myoglobin* (ng/mL) | 50.76 ± 31.39 | 36.80 ± 10.81 | 35.40 ± 20.87 | 0.262 | ||||
| Gender† | Male | 6 | 60.0% | 5 | 50.0% | 5 | 50.0% | 0.875 |
| Female | 4 | 40.0% | 5 | 50.0% | 5 | 50.0% | ||
BMI: body mass index; CPK: creatine phosphokinase; LDH: lactate dehydrogenase; CRP: C-reactive protein.
*Continuous variables are expressed as a mean ± standard deviation. P values correspond to one-way ANOVA test.
†Categorical variables are expressed as frequencies and percentages. P values correspond to Chi-squared test.
Figure 1Flowchart diagram of the study.
Blood concentrations for all groups at each follow-up period. Statistical significance and effect size for group-by-time interaction.
| Pre-T | Post-0 H | Post 2 H |
| Eta2 | ||
|---|---|---|---|---|---|---|
| Mean ± SD | Mean ± SD | Mean ± SD | ||||
| CPK (U/L) | Control | 74.90 ± 17.21 | 74.10 ± 17.12 | 74.40 ± 16.57 | 0.425 | 0.065 |
| Thoracic | 72.00 ± 13.73 | 72.10 ± 16.00 | 71.10 ± 19.09 | |||
| Cervical | 65.10 ± 14.78 | 65.20 ± 16.29 | 68.10 ± 16.38 | |||
|
| ||||||
| LDH (U/L) | Control | 276.03 ± 57.30 | 283.43 ± 44.29 | 268.11 ± 47.02 | 0.167 | 0.112 |
| Thoracic | 297.20 ± 52.66 | 294.70 ± 52.69 | 289.80 ± 67.36 | |||
| Cervical | 275.90 ± 43.40 | 276.00 ± 28.20 | 302.80 ± 82.64 | |||
|
| ||||||
| Enolase (ng/mL) | Control | 9.48 ± 1.81 | 8.90 ± 1.24 | 8.86 ± 1.29 | 0.235 | 0.100 |
| Thoracic | 9.09 ± 1.50 | 9.52 ± 1.41 | 9.42 ± 2.95 | |||
| Cervical | 9.57 ± 3.26 | 9.23 ± 1.97 | 11.57 ± 6.17 | |||
|
| ||||||
| CPR (mg/L) | Control | 1.41 ± 1.00 | 1.61 ± 1.02 | 1.53 ± 1.19 | 0.486 | 0.058 |
| Thoracic | 0.56 ± 0.30 | 0.50 ± 0.27 | 0.50 ± 0.30 | |||
| Cervical | 1.48 ± 1.16 | 1.48 ± 1.22 | 1.47 ± 1.15 | |||
|
| ||||||
| Aldolase (U/L) | Control | 3.09 ± 1.60 | 3.36 ± 1.37 | 3.50 ± 1.57 | 0.859 | 0.019 |
| Thoracic | 3.10 ± 1.06 | 3.23 ± 1.25 | 3.17 ± 1.37 | |||
| Cervical | 3.13 ± 1.02 | 3.29 ± 0.90 | 3.63 ± 1.38 | |||
|
| ||||||
| Myoglobin (ng/mL) | Control | 50.76 ± 31.39 | 52.18 ± 23.63 | 70.20 ± 43.56 | 0.312 | 0.083 |
| Thoracic | 36.80 ± 10.81 | 38.30 ± 10.80 | 36.60 ± 10.60 | |||
| Cervical | 35.40 ± 20.87 | 35.80 ± 19.62 | 39.10 ± 22.19 | |||
Pre-T: pretreatment values; Post-0 H: values 0 H after intervention; Post-2 H: values 2 H after intervention; CPK: creatine phosphokinase; LDH: lactate dehydrogenase; CRP: C-reactive protein.
Mean differences between control and both the thoracic and the cervical groups.
| Control-thoracic | Control-cervical | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Mean difference | 95% CI |
| Cohen- | Mean difference | 95% CI |
| Cohen- | ||
| CPK (U/L) | Pretreatment | 2.90 | (−14.57; 20.37) | 1.000 | 0.19 | 9.80 | (−7.67; 27.27) | 0.491 | 0.61 |
| Post 0 H | 2.00 | (−16.81; 20.81) | 1.000 | 0.12 | 8.90 | (−9.91; 27.71) | 0.713 | 0.53 | |
| Post 2 H | 3.30 | (−16.55; 23.15) | 1.000 | 0.18 | 6.30 | (−13.55; 26.15) | 1.000 | 0.38 | |
|
| |||||||||
| LDH (U/L) | Pretreatment | −21.17 | (−79.90; 37.55) | 1.000 | 0.38 | 0.13 | (−58.60; 58.85) | 1.000 | 0.00 |
| Post 0 H | −11.27 | (−60.29; 37.75) | 1.000 | 0.23 | 7.43 | (−41.59; 56.45) | 1.000 | 0.20 | |
| Post 2 H | −21.69 | (−98.48; 55.11) | 1.000 | 0.37 | −34.69 | (−111.48; 42.11) | 0.777 | 0.52 | |
|
| |||||||||
| Enolase (ng/mL) | Pretreatment | 0.39 | (−2.26; 3.04) | 1.000 | 0.23 | −0.09 | (−2.74; 2.56) | 1.000 | 0.04 |
| Post 0 H | −0.62 | (−2.42; 1.17) | 1.000 | 0.47 | −0.33 | (−2.13; 1.46) | 1.000 | 0.20 | |
| Post 2 H | −0.56 | (−5.15; 4.03) | 1.000 | 0.24 | −2.71 | (−7.30; 1.88) | 0.431 | 0.61 | |
|
| |||||||||
| CRP (mg/L) | Pretreatment | 0.85 | (−0.18; 1.88) | 0.136 | 1.14 | −0.07 | (−1.10; 0.96) | 1.000 | 0.07 |
| Post 0 H | 1.11 | (0.05; 2.18) |
| 1.49 | 0.13 | (−0.93; 1.20) | 1.000 | 0.12 | |
| Post 2 H | 1.03 | (−0.09; 2.14) | 0.078 | 1.18 | 0.06 | (−1.06; 1.17) | 1.000 | 0.05 | |
|
| |||||||||
| Aldolase (U/L) | Pretreatment | −0.01 | (−1.44; 1.43) | 1.000 | 0.00 | −0.04 | (−1.47; 1.40) | 1.000 | 0.03 |
| Post 0 H | 0.13 | (−1.23; 1.49) | 1.000 | 0.10 | 0.07 | (−1.29; 1.43) | 1.000 | 0.06 | |
| Post 2 H | 0.33 | (−1.32; 1.98) | 1.000 | 0.22 | −0.13 | (−1.78; 1.52) | 1.000 | 0.09 | |
|
| |||||||||
| Myoglobin (ng/mL) | Pretreatment | 13.96 | (−11.89; 39.80) | 0.538 | 0.59 | 15.36 | (−10.49; 41.20) | 0.423 | 0.58 |
| Post 0 H | 13.88 | (−7.57; 35.34) | 0.331 | 0.76 | 16.38 | (−5.07; 37.84) | 0.185 | 0.75 | |
| Post 2 H | 33.60 | (0.63; 66.57) | 0.045* | 1.06 | 31.10 | (−1.87; 64.07) | 0.069 | 0.90 | |
Pre-T: pretreatment values; Post-0 H: values 0 H after intervention; Post-2 H: values 2 H after intervention; CPK: creatine phosphokinase; LDH: lactate dehydrogenase; CRP: C-reactive protein.
*Trend to statistical significance.